Absci and EQRx in tie-up to accelerate production of cheaper, protein based therapeutics
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
